Given that the first CN-AML group (n = 129, aged <60 years) included a small number of patients who had received Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT), the prognostic value of MAP7 was further confirmed in the second independent group of CN-AML patients without AlloSCT who received intensive double induction and consolidation chemotherapy (n = 88, aged <60 years). The gene discussed is MAP7; the disease is acute myeloid leukemia.